Orrick advised BioAtla on the deal. Clinical-stage biotechnology company BioAtla, Inc. (Nasdaq: BCAB) announced the sale of 9,745,128 shares of its common stock at a price of...
Orrick advised BioAtla on the deal. Clinical-stage biotechnology company BioAtla, Inc. (Nasdaq: BCAB) announced the sale of 9,745,128 shares of its common stock at a price of...
You must be a Standard 1 Year member to access this content.